Tenvie Therapeutics Initiates First-in-Human Trial of CNS-Penetrant NLRP3 Inhibitor TNV262 for Obesity and Cardiovascular Disease
核心洞察
Tenvie Therapeutics (搜索) has dosed the first subject in a Phase 1 clinical trial of TNV262 (搜索), a fully CNS-penetrant small molecule NLRP3 (搜索) inhibitor targeting cardiometabolic diseases including obesity (搜索) and cardiovascular disease (搜索).
The Phase 1a/1b study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses in healthy volunteers and persons with obesity (搜索), with preliminary data expected in the second half of 2026.
TNV262 (搜索) represents the first clinical application of Tenvie's CNS-first design approach and is uniquely positioned to deliver disease-modifying effects by targeting neuroinflammation at the source of disease progression.
Tenvie Therapeutics (搜索) announced the dosing of the first subject in a Phase 1 clinical study evaluating TNV262 (搜索), a fully CNS-penetrant small molecule inhibitor targeting NLRP3 (搜索) for the treatment of cardiometabolic diseases, including obesity (搜索) and cardiovascular disease (搜索) (CVD), as well as multiple sclerosis (搜索) (MS). This milestone marks the first candidate from Tenvie's product engine to enter clinical development.
Novel CNS-First Design Approach
TNV262 (搜索) represents the first clinical application of Tenvie's CNS-first design approach, which builds maximum CNS penetration into the foundation of their chemistry to precisely engage key biological targets and intervene at the source of disease. "This trial represents the first clinical application of our CNS-first design approach—building maximum CNS penetration into the foundation of our chemistry to precisely engage key biological targets and intervene at the source of disease," said Tony Estrada, Ph.D., President & CEO of Tenvie Therapeutics (搜索).
The drug targets NLRP3 (搜索), a key regulator of inflammation within the innate immune system. According to Tanya Z. Fischer, M.D., Ph.D., Chief Medical Officer at Tenvie Therapeutics (搜索), "Dysregulation of the NLRP3 pathway has been implicated across multiple diseases characterized by chronic inflammation, including cardiometabolic conditions such as obesity (搜索) and CVD."
Addressing Limitations of Existing NLRP3 Programs
TNV262 (搜索) is designed to overcome a significant limitation in the field. "Although clinical validation of NLRP3 (搜索) has emerged in peripheral indications, many existing programs have been limited by insufficient CNS exposure," Fischer explained. "As a fully CNS-penetrant NLRP3 inhibitor supported by encouraging preclinical data demonstrating robust suppression of inflammatory CV risk biomarkers, TNV262 is uniquely positioned to deliver disease-modifying effects for people living with obesity (搜索) and CVD."
In preclinical studies, TNV262 (搜索) demonstrated complete CNS penetrance and a favorable safety profile, supporting its potential across inflammation- and neuroinflammation-driven diseases.
Phase 1 Trial Design and Endpoints
The Phase 1a/1b first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics of single and multiple ascending doses of TNV262 (搜索) in healthy volunteers and persons with obesity (搜索). Primary outcome measures include the safety and tolerability of TNV262, as well as biomarkers of inflammation and cardiometabolic risk.
Secondary outcome measures will assess body weight and body composition, along with measures of appetite and eating behavior in persons with obesity (搜索). Tenvie expects to report preliminary safety and pharmacokinetic data in the second half of 2026.
Clinical Significance and Future Development
The trial addresses a critical gap in current cardiometabolic care. "Despite important advances in cardiometabolic care, many existing therapies primarily address downstream risk factors rather than the biological processes that drive disease progression," said Donna Ryan, M.D., Professor Emerita at Pennington Biomedical Research Center. "Chronic, unresolved inflammation is increasingly recognized as a key contributor to obesity (搜索) and CVD, and approaches that target neuroinflammatory pathways such as NLRP3 (搜索) have the potential to meaningfully alter disease trajectory."
Pending positive results from the Phase 1 study, Tenvie intends to initiate Phase 2 studies evaluating TNV262 (搜索) in CVD and obesity (搜索), as well as in MS. The fully CNS-penetrant profile of TNV262 also supports its potential in other diseases characterized by neuroinflammation-mediated disease progression.
Company Pipeline and Platform
Tenvie Therapeutics (搜索) is developing precision-engineered small molecule therapies to address core drivers of neurological and peripheral diseases: neuroinflammation and cellular dysfunction. The company's proprietary product engine enables advancement of both fully CNS-penetrant and peripherally restricted products across a broad portfolio.
In parallel with TNV262 (搜索), Tenvie is advancing TNV108 (搜索), a peripherally restricted SARM1 (搜索) allosteric inhibitor targeting peripheral neuropathies, through preclinical development. The clinical pipeline is complemented by discovery-stage programs across a range of related indications.